Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

MM Tanner; JJ Isola; T Wiklund; B Erikstein; P Kellokumpu-Lehtinen; Per Malmström; N Wilking; J Nilsson; J Bergh

Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

MM Tanner, JJ Isola, T Wiklund, B Erikstein, P Kellokumpu-Lehtinen, Per Malmström, N Wilking, J Nilsson, J Bergh

Breastcancer-genetics

Research output: Contribution to journal › Published meeting abstract › peer-review

Original language	English
Pages (from-to)	841S-841S
Journal	Journal of Clinical Oncology
Volume	23
Issue number	16S
Publication status	Published - 2005
Event	2005 ASCO Annual Meeting - Duration: 0001 Jan 2 → …

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/9518

Cite this

Tanner, MM., Isola, JJ., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., Malmström, P., Wilking, N., Nilsson, J., & Bergh, J. (2005). Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. Journal of Clinical Oncology, 23(16S), 841S-841S. http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/9518

@article{d82ab9cb2c82482badf293ef72567e1e,

title = "Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.",

author = "MM Tanner and JJ Isola and T Wiklund and B Erikstein and P Kellokumpu-Lehtinen and Per Malmstr{\"o}m and N Wilking and J Nilsson and J Bergh",

year = "2005",

language = "English",

volume = "23",

pages = "841S--841S",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "Lippincott Williams & Wilkins",

number = "16S",

note = "2005 ASCO Annual Meeting ; Conference date: 02-01-0001",

}

Tanner, MM, Isola, JJ, Wiklund, T, Erikstein, B, Kellokumpu-Lehtinen, P, Malmström, P, Wilking, N, Nilsson, J & Bergh, J 2005, 'Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.', Journal of Clinical Oncology, vol. 23, no. 16S, pp. 841S-841S. <http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/9518>

Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. / Tanner, MM; Isola, JJ; Wiklund, T et al.
In: Journal of Clinical Oncology, Vol. 23, No. 16S, 2005, p. 841S-841S.

Research output: Contribution to journal › Published meeting abstract › peer-review

TY - JOUR

T1 - Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.

AU - Tanner, MM

AU - Isola, JJ

AU - Wiklund, T

AU - Erikstein, B

AU - Kellokumpu-Lehtinen, P

AU - Malmström, Per

AU - Wilking, N

AU - Nilsson, J

AU - Bergh, J

PY - 2005

Y1 - 2005

M3 - Published meeting abstract

SN - 1527-7755

VL - 23

SP - 841S-841S

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16S

T2 - 2005 ASCO Annual Meeting

Y2 - 2 January 0001

ER -